UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000049131 |
|---|---|
| Receipt number | R000055966 |
| Scientific Title | A survey of treatment practice for patients with neuromyelitis optica spectrum disorder under satralizumab treatment using Japanese claims database |
| Date of disclosure of the study information | 2022/10/07 |
| Last modified on | 2024/02/29 09:55:35 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A survey of treatment practice for patients with neuromyelitis optica spectrum disorder under satralizumab treatment using Japanese claims database
Acronym
A survey of treatment practice for patients with NMOSD under satralizumab treatment using Japanese claims database
Scientific Title
A survey of treatment practice for patients with neuromyelitis optica spectrum disorder under satralizumab treatment using Japanese claims database
Scientific Title:Acronym
A survey of treatment practice for patients with NMOSD under satralizumab treatment using Japanese claims database
Region
| Japan |
Condition
Condition
neuromyelitis optica spectrum disorder (NMOSD)
Classification by specialty
| Neurology | Ophthalmology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To describe usage of oral corticosteroids during maintenance phase of NMOSD under satralizumab treatment
Basic objectives2
Others
Basic objectives -Others
drug utilization
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Proportion of patients who reduced oral corticosteroid to 0 mg at day 360 without relapse under continuous satralizumab prescription
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients who were diagnosed as NMOSD and prescribed satralizumab at least once by March 2022 with more than 90 days of claim record prior to prescription of satralizumab
Key exclusion criteria
-
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | Katsuhisa |
| Middle name | |
| Last name | Yamashita |
Organization
CHUGAI PHARMACEUTICAL CO.,LTD.
Division name
Medical Affairs Div.
Zip code
1038324
Address
1-1 Nihonbashi-Muromachi 2-Chome, Chuo-Ku Tokyo
TEL
03-3273-0866
cma-clinicaltrial@chugai-pharm.co.jp
Public contact
Name of contact person
| 1st name | Nobuo |
| Middle name | |
| Last name | Nishijima |
Organization
CHUGAI PHARMACEUTICAL CO.,LTD.
Division name
Medical Affairs Div.
Zip code
1038324
Address
1-1 Nihonbashi-Muromachi 2-Chome, Chuo-Ku Tokyo
TEL
03-3273-0866
Homepage URL
cma-clinicaltrial@chugai-pharm.co.jp
Sponsor or person
Institute
CHUGAI PHARMACEUTICAL CO.,LTD.
Institute
Department
Personal name
Funding Source
Organization
Self-funding
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Non-Profit Organization MINS Institutional Review Board
Address
1-15-14, Dogenzaka, Shibuya, Tokyo, Japan
Tel
03-6416-1868
npo-mins@j-irb.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 10 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
https://pubmed.ncbi.nlm.nih.gov/38401202/
Number of participants that the trial has enrolled
131
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
| 2024 | Year | 02 | Month | 24 | Day |
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2022 | Year | 09 | Month | 26 | Day |
Date of IRB
| 2022 | Year | 10 | Month | 05 | Day |
Anticipated trial start date
| 2022 | Year | 10 | Month | 12 | Day |
Last follow-up date
| 2023 | Year | 04 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
| 2024 | Year | 02 | Month | 12 | Day |
Other
Other related information
[Organization for analysis]
Intage Healthcare Inc.
[Organization providing data]
Medical Data Vision Co.,Ltd.
Management information
Registered date
| 2022 | Year | 10 | Month | 05 | Day |
Last modified on
| 2024 | Year | 02 | Month | 29 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055966
